Early Access — free while we kick the tires
EdgarHawk

Jacobs Bruce N.

Chief Financial Officer

Officer
2 filings analyzed · 1 company · Latest 2026-03-04

Companies

Company Buys Sells Direction
Kymera Therapeutics, Inc. KYMR 0 10 Net selling

Activity

March 2026
low
Sell
12,471 shares
$1,091,231
Significance 3/10

CFO Jacobs sold 12,471 shares (12.5K shares) for $1,091,230.63 ($1.1M) across 7 transactions on 2026-03-02 to 2026-03-04.

Jacobs Bruce N., Chief Financial Officer at Kymr, executed 7 separate sales totaling 12,471 shares for $1,091,230.63 ($1.1M) across two trading days at prices ranging from $84.00 to $89.66, with a blended average of $87.50. This represents a 5.1% reduction in his holdings, leaving him with 232,588 shares post-transaction. The sales occurred as the stock traded near its 52-week high of $95.03 (current price $86.11 is 9.4% below that peak), and within a 30-day window of +13.9% appreciation. His prior sale at Kymr on 2025-09-17 saw the stock gain 68.4% in the 90-day period following, a pattern of poor timing that did not repeat here—though it is not yet possible to assess the full 90-day outcome of this March 2026 filing. The company remains unprofitable with a net income of $-82,175,000.00 against quarterly revenue of $2,764,000.00 and annual revenue decline of -16.7%, providing limited visibility into near-term cash generation.

September 2025
high
Sell
79,220 shares
$3,961,380
Significance 6/10

CFO Bruce N. Jacobs sold 79,220 shares of KYMR at $50.00 on 2025-09-17 for $3,961,380.26; reduced holdings 25.8% despite -40.1% revenue decline

CFO Bruce N. Jacobs sold 79,220 shares at $50.00, reducing his post-transaction holdings to 227,409 shares (a 25.8% reduction from 306,629 shares). The sale occurred as Kymera continues to operate unprofitably with net income of $-76,614,000.00 and annual revenue declining -40.1%. The timing of this material reduction in CFO stake—worth $3,961,380.26—while the company faces significant revenue headwinds and ongoing losses merits investor scrutiny regarding management confidence in near-term execution.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access